Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 57 | 2024 | 2401 | 5.490 |
Why?
|
Hepatitis, Autoimmune | 17 | 2023 | 173 | 4.520 |
Why?
|
Cholangitis, Sclerosing | 14 | 2024 | 179 | 2.820 |
Why?
|
Alagille Syndrome | 6 | 2023 | 45 | 1.850 |
Why?
|
Biliary Atresia | 14 | 2018 | 88 | 1.460 |
Why?
|
Liver Failure | 8 | 2013 | 252 | 1.360 |
Why?
|
Liver Diseases | 9 | 2023 | 1305 | 1.340 |
Why?
|
Hepatolenticular Degeneration | 3 | 2022 | 73 | 1.220 |
Why?
|
Immunosuppressive Agents | 21 | 2020 | 4206 | 1.130 |
Why?
|
End Stage Liver Disease | 4 | 2017 | 370 | 1.110 |
Why?
|
Hepatitis C | 5 | 2024 | 1595 | 0.920 |
Why?
|
Cholestasis | 6 | 2022 | 385 | 0.910 |
Why?
|
Graft Survival | 17 | 2021 | 3887 | 0.890 |
Why?
|
Graft Rejection | 12 | 2021 | 4492 | 0.850 |
Why?
|
Hypertension, Portal | 7 | 2022 | 230 | 0.850 |
Why?
|
Hepatopulmonary Syndrome | 2 | 2014 | 25 | 0.820 |
Why?
|
Hepacivirus | 4 | 2024 | 1344 | 0.780 |
Why?
|
Autoantibodies | 7 | 2018 | 2121 | 0.770 |
Why?
|
Azathioprine | 4 | 2018 | 354 | 0.740 |
Why?
|
Bile Ducts | 3 | 2012 | 288 | 0.670 |
Why?
|
Child | 76 | 2024 | 80917 | 0.660 |
Why?
|
Cholestasis, Intrahepatic | 4 | 2021 | 75 | 0.640 |
Why?
|
Antiviral Agents | 9 | 2024 | 3073 | 0.630 |
Why?
|
Liver | 15 | 2018 | 7577 | 0.610 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 2018 | 108 | 0.590 |
Why?
|
Fatty Liver | 3 | 2013 | 809 | 0.550 |
Why?
|
Tacrolimus | 6 | 2013 | 750 | 0.540 |
Why?
|
Pediatrics | 6 | 2017 | 3629 | 0.540 |
Why?
|
Bilirubin | 11 | 2021 | 438 | 0.540 |
Why?
|
Pancreas Transplantation | 1 | 2017 | 193 | 0.530 |
Why?
|
Lymphangioma | 1 | 2016 | 60 | 0.510 |
Why?
|
Liver Failure, Acute | 3 | 2014 | 182 | 0.500 |
Why?
|
Medication Adherence | 4 | 2013 | 2187 | 0.500 |
Why?
|
Hepatitis | 3 | 2007 | 227 | 0.500 |
Why?
|
Child, Preschool | 43 | 2023 | 42669 | 0.470 |
Why?
|
Organ Transplantation | 3 | 2015 | 1176 | 0.450 |
Why?
|
Hepatitis C, Chronic | 6 | 2024 | 1032 | 0.450 |
Why?
|
Fructose Intolerance | 1 | 2013 | 8 | 0.440 |
Why?
|
Gastroenterology | 2 | 2020 | 593 | 0.440 |
Why?
|
Hepatomegaly | 1 | 2013 | 84 | 0.430 |
Why?
|
Bile Ducts, Intrahepatic | 2 | 2021 | 304 | 0.420 |
Why?
|
Liver Neoplasms | 5 | 2017 | 4362 | 0.410 |
Why?
|
Cytochrome P-450 CYP2D6 | 3 | 2003 | 108 | 0.410 |
Why?
|
Autoimmunity | 2 | 2023 | 1361 | 0.410 |
Why?
|
Adolescent | 58 | 2024 | 89169 | 0.400 |
Why?
|
Lymphoproliferative Disorders | 3 | 2012 | 528 | 0.390 |
Why?
|
Anemia, Hemolytic, Autoimmune | 3 | 2011 | 147 | 0.390 |
Why?
|
Hyperplasia | 2 | 2014 | 1151 | 0.380 |
Why?
|
Muromonab-CD3 | 1 | 2011 | 104 | 0.380 |
Why?
|
Tyrosinemias | 1 | 2011 | 10 | 0.380 |
Why?
|
Hepatitis B, Chronic | 3 | 2010 | 413 | 0.370 |
Why?
|
Spleen | 1 | 2017 | 2295 | 0.370 |
Why?
|
Intestine, Small | 1 | 2017 | 1217 | 0.370 |
Why?
|
Infant | 35 | 2023 | 36535 | 0.360 |
Why?
|
Postoperative Complications | 14 | 2017 | 15832 | 0.360 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2257 | 0.360 |
Why?
|
Giant Cells | 3 | 2007 | 187 | 0.350 |
Why?
|
Portoenterostomy, Hepatic | 5 | 2018 | 22 | 0.350 |
Why?
|
Inflammatory Bowel Diseases | 5 | 2024 | 2442 | 0.340 |
Why?
|
Antilymphocyte Serum | 1 | 2011 | 492 | 0.330 |
Why?
|
Cefotaxime | 1 | 2009 | 36 | 0.330 |
Why?
|
Vancomycin | 2 | 2024 | 506 | 0.320 |
Why?
|
Humans | 115 | 2024 | 768166 | 0.320 |
Why?
|
Continuity of Patient Care | 3 | 2010 | 1078 | 0.310 |
Why?
|
Thrombocytopenia | 2 | 2016 | 1179 | 0.310 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2012 | 617 | 0.290 |
Why?
|
Treatment Outcome | 34 | 2024 | 65371 | 0.290 |
Why?
|
Cholelithiasis | 1 | 2009 | 408 | 0.290 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2017 | 2333 | 0.290 |
Why?
|
Hyperbilirubinemia, Neonatal | 1 | 2007 | 30 | 0.290 |
Why?
|
Cholangiocarcinoma | 1 | 2013 | 561 | 0.280 |
Why?
|
Bile Duct Neoplasms | 1 | 2013 | 614 | 0.280 |
Why?
|
Self Concept | 1 | 2013 | 1043 | 0.270 |
Why?
|
Caroli Disease | 1 | 2006 | 12 | 0.270 |
Why?
|
Ursodeoxycholic Acid | 2 | 2021 | 81 | 0.260 |
Why?
|
Bile Acids and Salts | 2 | 2021 | 398 | 0.260 |
Why?
|
Williams Syndrome | 1 | 2007 | 195 | 0.240 |
Why?
|
Male | 68 | 2024 | 364719 | 0.240 |
Why?
|
Polycystic Kidney Diseases | 1 | 2006 | 133 | 0.240 |
Why?
|
Methylprednisolone | 3 | 2016 | 386 | 0.240 |
Why?
|
Affect | 1 | 2013 | 1495 | 0.240 |
Why?
|
Pemphigoid, Bullous | 1 | 2006 | 110 | 0.240 |
Why?
|
Interferon-alpha | 2 | 2010 | 910 | 0.240 |
Why?
|
Eosinophilia | 2 | 2012 | 556 | 0.230 |
Why?
|
Female | 68 | 2024 | 397192 | 0.230 |
Why?
|
Infant, Newborn | 17 | 2021 | 26422 | 0.230 |
Why?
|
Treatment Refusal | 2 | 2006 | 433 | 0.220 |
Why?
|
Avitaminosis | 2 | 2014 | 35 | 0.220 |
Why?
|
Alanine Transaminase | 6 | 2021 | 606 | 0.220 |
Why?
|
Jaundice | 1 | 2004 | 95 | 0.220 |
Why?
|
Rubella | 1 | 2023 | 55 | 0.220 |
Why?
|
Lamivudine | 1 | 2005 | 367 | 0.210 |
Why?
|
Chickenpox | 1 | 2023 | 95 | 0.210 |
Why?
|
Mycophenolic Acid | 1 | 2005 | 348 | 0.210 |
Why?
|
Mumps | 1 | 2023 | 71 | 0.210 |
Why?
|
Trientine | 1 | 2022 | 12 | 0.210 |
Why?
|
Penicillamine | 1 | 2022 | 60 | 0.200 |
Why?
|
Prednisolone | 3 | 2014 | 326 | 0.200 |
Why?
|
Immunodominant Epitopes | 1 | 2003 | 244 | 0.190 |
Why?
|
Quality of Life | 6 | 2014 | 13490 | 0.190 |
Why?
|
Hemangioendothelioma | 2 | 2013 | 112 | 0.190 |
Why?
|
Measles | 1 | 2023 | 180 | 0.190 |
Why?
|
Cystic Fibrosis | 1 | 2011 | 1294 | 0.190 |
Why?
|
Lung Transplantation | 1 | 2011 | 1309 | 0.190 |
Why?
|
Risk Factors | 18 | 2021 | 74944 | 0.180 |
Why?
|
Chelating Agents | 1 | 2022 | 385 | 0.180 |
Why?
|
Cysts | 1 | 2006 | 685 | 0.180 |
Why?
|
Adult | 28 | 2024 | 223646 | 0.180 |
Why?
|
Copper | 1 | 2022 | 368 | 0.170 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 2020 | 113 | 0.160 |
Why?
|
Follow-Up Studies | 14 | 2021 | 39348 | 0.160 |
Why?
|
Retrospective Studies | 22 | 2024 | 81762 | 0.160 |
Why?
|
Viral Vaccines | 1 | 2023 | 596 | 0.150 |
Why?
|
Sirolimus | 1 | 2005 | 1540 | 0.150 |
Why?
|
Immunologic Factors | 1 | 2007 | 1596 | 0.150 |
Why?
|
Failure to Thrive | 1 | 2018 | 139 | 0.150 |
Why?
|
Young Adult | 16 | 2024 | 60066 | 0.140 |
Why?
|
Enterohepatic Circulation | 1 | 2017 | 12 | 0.140 |
Why?
|
Biopsy | 7 | 2020 | 6793 | 0.140 |
Why?
|
Incidental Findings | 2 | 2013 | 698 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1886 | 0.140 |
Why?
|
Self Care | 2 | 2013 | 799 | 0.140 |
Why?
|
Adenosine Triphosphatases | 1 | 2021 | 842 | 0.140 |
Why?
|
Glucocorticoids | 3 | 2021 | 2167 | 0.140 |
Why?
|
Gallbladder | 3 | 2017 | 308 | 0.140 |
Why?
|
Ultrasonography | 2 | 2013 | 6004 | 0.140 |
Why?
|
Transplantation | 2 | 2010 | 221 | 0.130 |
Why?
|
Autoantigens | 2 | 2015 | 890 | 0.130 |
Why?
|
Age Factors | 7 | 2021 | 18412 | 0.120 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1363 | 0.120 |
Why?
|
Patient Compliance | 5 | 2013 | 2697 | 0.120 |
Why?
|
Hepatorenal Syndrome | 1 | 2016 | 76 | 0.120 |
Why?
|
Body Weight | 4 | 2018 | 4627 | 0.120 |
Why?
|
Cholangiography | 2 | 2020 | 182 | 0.120 |
Why?
|
North America | 2 | 2016 | 1289 | 0.120 |
Why?
|
Prognosis | 9 | 2021 | 30010 | 0.120 |
Why?
|
Time Factors | 9 | 2021 | 40218 | 0.120 |
Why?
|
Hepatoblastoma | 1 | 2015 | 90 | 0.120 |
Why?
|
Fatal Outcome | 2 | 2017 | 1836 | 0.120 |
Why?
|
Propranolol | 2 | 2013 | 493 | 0.110 |
Why?
|
Risk Assessment | 7 | 2021 | 24315 | 0.110 |
Why?
|
gamma-Glutamyltransferase | 3 | 2021 | 144 | 0.110 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 13014 | 0.110 |
Why?
|
Donor Selection | 1 | 2016 | 240 | 0.110 |
Why?
|
Survival Rate | 4 | 2013 | 12840 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5889 | 0.110 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2016 | 425 | 0.110 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1960 | 0.110 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 2013 | 43 | 0.110 |
Why?
|
Vitamin K | 2 | 2014 | 314 | 0.110 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 371 | 0.110 |
Why?
|
Vincristine | 1 | 2016 | 1040 | 0.110 |
Why?
|
Steroids | 1 | 2018 | 938 | 0.110 |
Why?
|
Sarcopenia | 1 | 2018 | 378 | 0.110 |
Why?
|
Jejunum | 2 | 2012 | 475 | 0.100 |
Why?
|
Liver Function Tests | 2 | 2012 | 526 | 0.100 |
Why?
|
Databases, Factual | 4 | 2015 | 8080 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2010 | 1126 | 0.100 |
Why?
|
Reoperation | 5 | 2014 | 4329 | 0.100 |
Why?
|
Recurrence | 5 | 2021 | 8509 | 0.100 |
Why?
|
Severity of Illness Index | 5 | 2024 | 15948 | 0.100 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2015 | 283 | 0.100 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 583 | 0.100 |
Why?
|
Vitamin E | 2 | 2014 | 874 | 0.100 |
Why?
|
Viremia | 2 | 2012 | 726 | 0.100 |
Why?
|
Hemoglobin SC Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2011 | 29 | 0.100 |
Why?
|
Acetylcysteine | 1 | 2013 | 262 | 0.090 |
Why?
|
Stomach | 1 | 2016 | 701 | 0.090 |
Why?
|
Consanguinity | 1 | 2013 | 460 | 0.090 |
Why?
|
Serum Albumin | 3 | 2021 | 677 | 0.090 |
Why?
|
Calculi | 1 | 2011 | 48 | 0.090 |
Why?
|
Microsomes, Liver | 2 | 2003 | 174 | 0.090 |
Why?
|
Mycoplasma pneumoniae | 1 | 2010 | 43 | 0.090 |
Why?
|
Peptide Fragments | 2 | 2003 | 5151 | 0.090 |
Why?
|
Endoscopy, Digestive System | 1 | 2013 | 358 | 0.090 |
Why?
|
Pneumonia, Mycoplasma | 1 | 2010 | 50 | 0.090 |
Why?
|
Graves Disease | 1 | 2012 | 239 | 0.090 |
Why?
|
Obesity | 1 | 2013 | 13090 | 0.090 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2010 | 86 | 0.090 |
Why?
|
Antimetabolites | 1 | 2010 | 128 | 0.090 |
Why?
|
Antibodies, Monoclonal | 1 | 2007 | 9263 | 0.090 |
Why?
|
HLA Antigens | 1 | 2015 | 1334 | 0.090 |
Why?
|
Blood Coagulation | 1 | 2016 | 1162 | 0.080 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 840 | 0.080 |
Why?
|
Anti-Bacterial Agents | 2 | 2024 | 7477 | 0.080 |
Why?
|
Aspartate Aminotransferases | 3 | 2021 | 414 | 0.080 |
Why?
|
Premature Birth | 1 | 2021 | 1829 | 0.080 |
Why?
|
Allopurinol | 1 | 2010 | 202 | 0.080 |
Why?
|
Disease Progression | 4 | 2021 | 13671 | 0.080 |
Why?
|
Cholagogues and Choleretics | 1 | 2008 | 39 | 0.080 |
Why?
|
Acalculous Cholecystitis | 1 | 2008 | 8 | 0.080 |
Why?
|
Transaminases | 2 | 2010 | 199 | 0.080 |
Why?
|
Cohort Studies | 8 | 2024 | 41754 | 0.080 |
Why?
|
Varicose Veins | 1 | 2010 | 158 | 0.080 |
Why?
|
Ganciclovir | 1 | 2009 | 256 | 0.080 |
Why?
|
Pilot Projects | 2 | 2013 | 8741 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 2013 | 1622 | 0.080 |
Why?
|
Self Efficacy | 1 | 2013 | 643 | 0.080 |
Why?
|
Health Behavior | 2 | 2010 | 2650 | 0.080 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2010 | 232 | 0.080 |
Why?
|
Administration, Oral | 3 | 2024 | 4030 | 0.070 |
Why?
|
Ribavirin | 1 | 2010 | 395 | 0.070 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 1926 | 0.070 |
Why?
|
Polyethylene Glycols | 2 | 2012 | 1196 | 0.070 |
Why?
|
Drug Monitoring | 2 | 2013 | 964 | 0.070 |
Why?
|
Mentors | 1 | 2013 | 671 | 0.070 |
Why?
|
Regression Analysis | 3 | 2013 | 6340 | 0.070 |
Why?
|
Body Image | 1 | 2013 | 646 | 0.070 |
Why?
|
Esophageal and Gastric Varices | 1 | 2010 | 215 | 0.070 |
Why?
|
Peer Group | 1 | 2013 | 700 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7454 | 0.070 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 246 | 0.070 |
Why?
|
Patient Dropouts | 1 | 2009 | 411 | 0.070 |
Why?
|
Fibrosis | 1 | 2014 | 2080 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 2 | 2002 | 2474 | 0.070 |
Why?
|
Hemangioma | 1 | 2011 | 727 | 0.070 |
Why?
|
Tissue Donors | 1 | 2016 | 2381 | 0.070 |
Why?
|
Choledochal Cyst | 1 | 2006 | 25 | 0.060 |
Why?
|
Abnormalities, Multiple | 1 | 2013 | 1424 | 0.060 |
Why?
|
Prospective Studies | 9 | 2021 | 54926 | 0.060 |
Why?
|
Diabetes Complications | 1 | 2012 | 1320 | 0.060 |
Why?
|
United States | 8 | 2020 | 73039 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3436 | 0.060 |
Why?
|
Transplants | 1 | 2007 | 208 | 0.060 |
Why?
|
Vasculitis | 1 | 2009 | 525 | 0.060 |
Why?
|
Registries | 4 | 2021 | 8375 | 0.060 |
Why?
|
Platelet Count | 2 | 2020 | 787 | 0.060 |
Why?
|
Food Hypersensitivity | 1 | 2012 | 734 | 0.060 |
Why?
|
Canada | 3 | 2015 | 2130 | 0.060 |
Why?
|
Granuloma, Plasma Cell | 1 | 2005 | 80 | 0.060 |
Why?
|
Colon | 1 | 2012 | 1801 | 0.060 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 696 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2010 | 1273 | 0.060 |
Why?
|
Chickenpox Vaccine | 1 | 2023 | 39 | 0.060 |
Why?
|
Chronic Disease | 4 | 2013 | 9384 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 3814 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2012 | 1388 | 0.050 |
Why?
|
Metabolic Diseases | 1 | 2010 | 684 | 0.050 |
Why?
|
Double-Blind Method | 5 | 2018 | 12465 | 0.050 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1206 | 0.050 |
Why?
|
Vaccines, Combined | 1 | 2023 | 70 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6082 | 0.050 |
Why?
|
Abdominal Neoplasms | 1 | 2005 | 287 | 0.050 |
Why?
|
Fibrosarcoma | 1 | 2005 | 313 | 0.050 |
Why?
|
Dietary Supplements | 2 | 2014 | 3445 | 0.050 |
Why?
|
Adolescent Behavior | 1 | 2011 | 1186 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2009 | 837 | 0.050 |
Why?
|
Radioligand Assay | 1 | 2002 | 366 | 0.050 |
Why?
|
Remission Induction | 2 | 2024 | 2410 | 0.050 |
Why?
|
Vaccines, Attenuated | 1 | 2023 | 314 | 0.050 |
Why?
|
Ischemia | 1 | 2011 | 1900 | 0.050 |
Why?
|
Epitope Mapping | 1 | 2003 | 301 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2015 | 3114 | 0.050 |
Why?
|
Postoperative Period | 1 | 2006 | 1826 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2013 | 1946 | 0.050 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2002 | 238 | 0.050 |
Why?
|
Echocardiography | 1 | 2014 | 5047 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14783 | 0.050 |
Why?
|
Health Status | 1 | 2014 | 4091 | 0.050 |
Why?
|
Cross Reactions | 1 | 2003 | 828 | 0.050 |
Why?
|
Vitamin A | 2 | 2014 | 611 | 0.040 |
Why?
|
Models, Statistical | 2 | 2013 | 5107 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6974 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2337 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2005 | 4568 | 0.040 |
Why?
|
Codon, Nonsense | 1 | 2021 | 287 | 0.040 |
Why?
|
Caregivers | 2 | 2009 | 2302 | 0.040 |
Why?
|
Postoperative Care | 2 | 2018 | 1480 | 0.040 |
Why?
|
Viral Nonstructural Proteins | 1 | 2020 | 228 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2014 | 2230 | 0.040 |
Why?
|
Hemorrhage | 1 | 2011 | 3467 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2012 | 3986 | 0.040 |
Why?
|
Acute Kidney Injury | 1 | 2010 | 1942 | 0.040 |
Why?
|
Quality Improvement | 1 | 2013 | 3857 | 0.040 |
Why?
|
Insulin | 1 | 2012 | 6607 | 0.040 |
Why?
|
Blood Glucose | 1 | 2012 | 6430 | 0.040 |
Why?
|
Reference Values | 2 | 2018 | 4938 | 0.040 |
Why?
|
Living Donors | 2 | 2013 | 647 | 0.030 |
Why?
|
Survival Analysis | 3 | 2021 | 10101 | 0.030 |
Why?
|
Cephalometry | 1 | 2018 | 380 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20760 | 0.030 |
Why?
|
Prevalence | 2 | 2012 | 15869 | 0.030 |
Why?
|
Comorbidity | 2 | 2010 | 10590 | 0.030 |
Why?
|
Recovery of Function | 1 | 2006 | 2981 | 0.030 |
Why?
|
Sex Factors | 1 | 2010 | 10632 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1008 | 0.030 |
Why?
|
Cytosol | 1 | 1999 | 887 | 0.030 |
Why?
|
Epitopes | 1 | 2002 | 2528 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1599 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 4055 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2015 | 187 | 0.030 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 26 | 0.030 |
Why?
|
Self Administration | 2 | 2008 | 386 | 0.030 |
Why?
|
Patient Selection | 1 | 2007 | 4260 | 0.030 |
Why?
|
Hypoalbuminemia | 1 | 2015 | 90 | 0.030 |
Why?
|
Enterostomy | 1 | 2014 | 14 | 0.030 |
Why?
|
Body Mass Index | 1 | 2012 | 13053 | 0.030 |
Why?
|
Ascites | 1 | 2015 | 338 | 0.030 |
Why?
|
Adrenergic beta-2 Receptor Antagonists | 1 | 2013 | 12 | 0.030 |
Why?
|
Los Angeles | 1 | 2013 | 245 | 0.030 |
Why?
|
Congenital Hypothyroidism | 1 | 2013 | 40 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1969 | 0.030 |
Why?
|
Child Development | 2 | 2018 | 2330 | 0.030 |
Why?
|
Membrane Glycoproteins | 1 | 2023 | 3711 | 0.030 |
Why?
|
Retinol-Binding Proteins | 1 | 2012 | 67 | 0.030 |
Why?
|
Prothrombin Time | 1 | 2012 | 117 | 0.030 |
Why?
|
Hepatitis A Antibodies | 1 | 2012 | 19 | 0.030 |
Why?
|
Methimazole | 1 | 2012 | 41 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3621 | 0.030 |
Why?
|
Antithyroid Agents | 1 | 2012 | 72 | 0.020 |
Why?
|
Free Radical Scavengers | 1 | 2013 | 213 | 0.020 |
Why?
|
Splenomegaly | 1 | 2012 | 192 | 0.020 |
Why?
|
alpha-Tocopherol | 1 | 2012 | 127 | 0.020 |
Why?
|
Hepatic Encephalopathy | 1 | 2013 | 144 | 0.020 |
Why?
|
Hepatitis A | 1 | 2012 | 126 | 0.020 |
Why?
|
Parents | 1 | 2005 | 3595 | 0.020 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2006 | 4640 | 0.020 |
Why?
|
Thyroid Function Tests | 1 | 2012 | 289 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2003 | 13421 | 0.020 |
Why?
|
Growth Disorders | 1 | 2015 | 635 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2008 | 10266 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1798 | 0.020 |
Why?
|
Pigmentation | 1 | 2011 | 143 | 0.020 |
Why?
|
Hepatic Duct, Common | 1 | 2010 | 48 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2023 | 4937 | 0.020 |
Why?
|
Blister | 1 | 2010 | 88 | 0.020 |
Why?
|
Placebos | 1 | 2014 | 1667 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2003 | 17622 | 0.020 |
Why?
|
Viral Load | 2 | 2010 | 3396 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13676 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4530 | 0.020 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 419 | 0.020 |
Why?
|
Vitamin D | 2 | 2014 | 3311 | 0.020 |
Why?
|
Sclerosis | 1 | 2010 | 211 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2003 | 4793 | 0.020 |
Why?
|
Thyroxine | 1 | 2013 | 665 | 0.020 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 656 | 0.020 |
Why?
|
Hypersensitivity, Immediate | 1 | 2012 | 349 | 0.020 |
Why?
|
Hepatic Artery | 1 | 2010 | 232 | 0.020 |
Why?
|
Middle Aged | 5 | 2012 | 223492 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 594 | 0.020 |
Why?
|
Venules | 1 | 2009 | 161 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 15454 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2012 | 991 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2012 | 1609 | 0.020 |
Why?
|
Mutation | 1 | 2013 | 30238 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12077 | 0.020 |
Why?
|
Drainage | 1 | 2014 | 1183 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 1998 | 1805 | 0.020 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2011 | 520 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 6316 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2013 | 718 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12252 | 0.020 |
Why?
|
Portal Vein | 1 | 2010 | 435 | 0.020 |
Why?
|
Adolescent Health Services | 1 | 2009 | 220 | 0.020 |
Why?
|
Physicians | 1 | 2005 | 4598 | 0.020 |
Why?
|
Kidney | 1 | 2003 | 7064 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2013 | 757 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1528 | 0.020 |
Why?
|
Aged | 4 | 2012 | 171504 | 0.020 |
Why?
|
Vitamins | 1 | 2014 | 1638 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2012 | 1243 | 0.020 |
Why?
|
Depression | 1 | 2005 | 8230 | 0.020 |
Why?
|
Dermatitis, Atopic | 1 | 2012 | 737 | 0.010 |
Why?
|
Drug Resistance, Viral | 1 | 2010 | 869 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2009 | 753 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2002 | 20227 | 0.010 |
Why?
|
Rhinitis | 1 | 2012 | 753 | 0.010 |
Why?
|
Hospitals, Pediatric | 1 | 2013 | 1876 | 0.010 |
Why?
|
Social Class | 1 | 2013 | 2008 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2381 | 0.010 |
Why?
|
Body Height | 1 | 2010 | 1565 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2193 | 0.010 |
Why?
|
HIV Infections | 1 | 2010 | 17569 | 0.010 |
Why?
|
Psychological Tests | 1 | 2005 | 643 | 0.010 |
Why?
|
Hepatocytes | 1 | 2010 | 1247 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 1119 | 0.010 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2008 | 843 | 0.010 |
Why?
|
Antigen-Antibody Reactions | 1 | 2002 | 342 | 0.010 |
Why?
|
DNA, Viral | 1 | 2009 | 2204 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2013 | 5315 | 0.010 |
Why?
|
Binding Sites, Antibody | 1 | 2002 | 340 | 0.010 |
Why?
|
Immune Sera | 1 | 2002 | 605 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2013 | 26379 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2010 | 4833 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13290 | 0.010 |
Why?
|
Binding, Competitive | 1 | 2002 | 1142 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2010 | 1791 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2010 | 1323 | 0.010 |
Why?
|
Attitude | 1 | 2005 | 771 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2005 | 13586 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2010 | 6514 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4146 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2015 | 4262 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6526 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3721 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 30256 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 14164 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2010 | 2100 | 0.010 |
Why?
|
Surface Properties | 1 | 2002 | 1166 | 0.010 |
Why?
|
Communication | 1 | 2013 | 3905 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2002 | 1683 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12543 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 2873 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2002 | 2748 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 370 | 0.010 |
Why?
|
Thrombosis | 1 | 2010 | 2957 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 13045 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 21538 | 0.010 |
Why?
|
Heart Transplantation | 1 | 2008 | 3301 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22291 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11878 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2002 | 3740 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5863 | 0.010 |
Why?
|
Depressive Disorder | 1 | 2005 | 3721 | 0.010 |
Why?
|
Models, Molecular | 1 | 2002 | 5403 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 3728 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1997 | 2862 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2012 | 59629 | 0.000 |
Why?
|